Adial Pharmaceuticals, Inc. has filed a Fast Track application with the US Food and Drug Administration (FDA) for its lead drug candidate, AD04. The drug is meant to target people with specific genes for whom other alcohol addiction therapies have failed. To take the drugs, a person must be diagnosed with alcohol use disorder.
Why Fast-Track AD04?
Several medication-assisted treatment options exist for alcoholics, but they are not considered to fail-proof or even useful for most people. They also carry a level of stigma that prevents doctors from prescribing them.
In America, treatment for alcohol use disorder often focuses on total abstinence, which many people with alcohol use disorder reject or, for whatever reason, are unable to achieve. While several drugs, including Topomax, have shown to be effective at preventing compulsive drinking, few treatment centers feel comfortable recommending a drug that allows people to continue drinking. (Other drugs make people …